ReviewFrontiers in cellular and infection microbiology2022
What Is New in the Anti-
Review in Frontiers in cellular and infection microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 55 citations in OpenAlex.
- Phosphoenolpyruvate Carboxykinase ControlsBiology · 2026Article
- Review
- Generative active learning guided discovery of a tobramycin and ciprofloxacin adjuvant against multidrug-resistantActa pharmaceutica Sinica. B · 2026Article
- FleQ-Dependent regulation of the ribonucleotide reductase repressor NrdR in Pseudomonas aeruginosa during biofilm growth and infection.Scientific reports · 2025Article
- Repurposing MK-8245 as a Quorum Sensing Inhibitor to Suppress Virulence and Potentiate Antibiotic Activity inAntibiotics (Basel, Switzerland) · 2025Article
- Rational Design, Computational Analysis and Antibacterial Activities of Synthesized Peptide-Based Molecules Targeting Quorum Sensing-Dependent Biofilm Formation inPharmaceuticals (Basel, Switzerland) · 2025Article
- Dosing and Delivery of Bacteriophage Therapy In a Murine Wound Infection Model.bioRxiv : the preprint server for biology · 2025Article
- Reviving the past for a healthier future: ancient molecules and remedies as a solution to the antibiotic crisis.Future microbiology · 2025Review
- Investigating the validity of mCIM and sCIM phenotypic methods in screening Pseudomonas aeruginosa isolates producing IMP, VIM, and NDM metallo-beta-lactamases isolated from burn wounds.The Journal of antibiotics · 2025Article
- Phage therapeutic delivery methods and clinical trials for combating clinically relevant pathogens.Therapeutic delivery · 2025Review
- Novel broadly reactive monoclonal antibody protects againstInfection and immunity · 2025Article
- Host-mimicking conditions promoteFrontiers in microbiology · 2025Article
- The efficacy and safety of ceftazidime/avibactam or polymyxin B based regimens forFrontiers in pharmacology · 2025Article
- Genomic virulence markers are associated with severe outcomes in patients with Pseudomonas aeruginosa bloodstream infection.Communications medicine · 2024Article
- Ser/Thr protein kinase Stk1 phosphorylates the key transcriptional regulator AlgR to modulate virulence and resistance inVirulence · 2024Article
- Antibiotic Resistance in the Elderly: Mechanisms, Risk Factors, and Solutions.Microorganisms · 2024Review
- AAV-vectored expression of monospecific or bispecific monoclonal antibodies protects mice from lethal Pseudomonas aeruginosa pneumonia.Gene therapy · 2024Article
- Miconazole and phenothiazine hinder the quorum sensing regulated virulence in Pseudomonas aeruginosa.The Journal of antibiotics · 2024Article
- Unveiling therapeutic efficacy of extract and multi-targeting phytocompounds fromRSC advances · 2024Article
- Evolution of two metabolic genes involved in nucleotide and amino acid metabolism in Pseudomonas aeruginosa.PloS one · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The spread of antibiotic-resistant bacteria poses a substantial threat to morbidity and mortality worldwide. Carbapenem-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.